Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jcmm.12422 http://scihub22266oqcxt.onion/10.1111/jcmm.12422 C4407600!4407600!25594563     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Cell+Mol+Med 2015 ; 19 (2): 265-82 Nephropedia Template TP {{tp|p=25594563|t=2015. A novel therapeutic effect of statins on nephrogenic diabetes insipidus |pdf=|usr=}}{{25594563}} gab.com Text A novel therapeutic effect of statins on nephrogenic diabetes insipidus JO: J Cell Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=25594563 #FOAvip Statins competitively inhibit hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase, resulting in reduced plasma total and low-density lipoprotein cholesterol levels. Recently, it has been shown that statins exert additional ?pleiotropic? effects by increasing expression levels of the membrane water channels aquaporin 2 (AQP2). AQP2 is localized mainly in the kidney and plays a critical role in determining cellular water content. This additional effect is independent of cholesterol homoeostasis, and depends on depletion of mevalonate-derived intermediates of sterol synthetic pathways, i.e. farnesylpyrophosphate and geranylgeranylpyrophosphate. By up-regulating the expression levels of AQP2, statins increase water reabsorption by the kidney, thus opening up a new avenue in treating patients with nephrogenic diabetes insipidus (NDI), a hereditary disease that yet lacks high-powered and limited side effects therapy. Aspects related to water balance determined by AQP2 in the kidney, as well as standard and novel therapeutic strategies of NDI are discussed. Twit Text FOAVip A novel therapeutic effect of statins on nephrogenic diabetes insipidus ????J Cell Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=25594563 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25594563 #FOAvip English Wikipedia <ref>{{Cite pmid|25594563}}</ref> A novel therapeutic effect of statins on nephrogenic diabetes insipidus #MMPMID25594563 Bonfrate L; Procino G; Wang DQH; Svelto M; Portincasa P J Cell Mol Med 2015[Feb]; 19 (2): 265-82 PMID25594563show ga Statins competitively inhibit hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase, resulting in reduced plasma total and low-density lipoprotein cholesterol levels. Recently, it has been shown that statins exert additional ?pleiotropic? effects by increasing expression levels of the membrane water channels aquaporin 2 (AQP2). AQP2 is localized mainly in the kidney and plays a critical role in determining cellular water content. This additional effect is independent of cholesterol homoeostasis, and depends on depletion of mevalonate-derived intermediates of sterol synthetic pathways, i.e. farnesylpyrophosphate and geranylgeranylpyrophosphate. By up-regulating the expression levels of AQP2, statins increase water reabsorption by the kidney, thus opening up a new avenue in treating patients with nephrogenic diabetes insipidus (NDI), a hereditary disease that yet lacks high-powered and limited side effects therapy. Aspects related to water balance determined by AQP2 in the kidney, as well as standard and novel therapeutic strategies of NDI are discussed. äA novel therapeutic effect of statins on nephrogenic diabetes insipidu(epmc).pdf DeepDyve Pubget Overpricing